Drug Database · Clinicians

Cisplatin

Brands (32) Cisplaget, Ebeplatin, Neoplatin…Show all

Platinum-based Drug US FDA class
Antineoplastic agent (platinum compound); Antineoplastic (cell cycle-specific agent); and others PH FDA category

Rx · Prescription drug41 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b2b029f5-0d7e-4e7f-accc-b722aec34c68, version date December 3, 2024 (Cisplatin · Accord Healthcare Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Advanced testicular cancer
  • Advanced ovarian cancer
  • Advanced bladder cancer
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Cisplatin injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer (1.1) • Advanced ovarian cancer (1.2) • Advanced bladder cancer (1.3) 1.1 Advanced Testicular Cancer Cisplatin injection is indicated for the treatment of advanced testicular cancer. 1.2 Advanced Ovarian Cancer Cisplatin injection is indicated for the treatment of advanced ovarian cancer. 1.3 Advanced Bladder Cancer Cisplatin injection is indicated for the treatment of advanced bladder cancer.

Contraindications

4 CONTRAINDICATIONS Cisplatin injection is contraindicated in patients with severe hypersensitivity to cisplatin [see Warnings and Precautions (5.4)]. Severe hypersensitivity to cisplatin (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Administer pre-treatment hydration and pre- and post-treatment antiemetics. (2.1)
  • • Cisplatin injection has been administered intravenously at: o Advanced testicular cancer: 20 mg/m2 daily for 5 days per cycle (2.2)
  • o Advanced ovarian cancer: 75 mg/m2 to 100 mg/m2 per cycle once every 3 to 4 weeks (2.3)
  • o Advanced bladder cancer: 50 mg/m2 to 70 mg/m2 intravenously per cycle once every 3 to 4 weeks (2.4)
  • Refer to current treatment guidelines for specific dosing information. • Administer by slow intravenous infusion. Avoid contact of cisplatin injection with aluminum parts. (2.6)
2.1 Hydration and Anti-Emetic Treatment

2.1 Hydration and Anti-Emetic Treatment Patients treated with cisplatin injection must receive appropriate pre-treatment hydration. Maintain adequate hydration and urinary output for 24 hours after cisplatin injection administration [see Warnings and Precautions (5.1)]. Administer pre-treatment and post-treatment antiemetics as appropriate [see Warnings and Precautions (5.7)].

2.2 Advanced Testicular Cancer

2.2 Advanced Testicular Cancer Cisplatin injection has been administered at 20 mg/m 2 intravenously daily for 5 days per cycle. Other doses and combination regimens have been used.

2.3 Advanced Ovarian Cancer

2.3 Advanced Ovarian Cancer Cisplatin injection has been administered at 75 mg/m 2 to 100 mg/m 2 intravenously per cycle once every 3 to 4 weeks on Day 1. Other doses and combination regimens have been used.

2.4 Advanced Bladder Cancer

2.4 Advanced Bladder Cancer Cisplatin injection has been administered at 50 mg/m 2 to 70 mg/m 2 intravenously per cycle once every 3 to 4 weeks. For heavily pretreated patients, an initial dose of 50 mg/m 2 per cycle repeated every 4 weeks is recommended. Other doses and combination in regimens have been used.

2.5 Dose Modifications

2.5 Dose Modifications Consider alternative treatments or dose reductions for patients with impaired creatinine clearance, myelosuppression, or neuropathy. Consider permanent discontinuation for Grade 3-4 neuropathy. [See Warnings and Precautions (5.1)]

2.6 Preparation, Handling, and Administration

2.6 Preparation, Handling, and Administration Do not use needles or intravenous sets containing aluminum parts that can come in contact with cisplatin injection during preparation or administration. Aluminum reacts with cisplatin injection, causing precipitate formation and a loss of potency. Cisplatin injection is a cytotoxic drug.

Follow applicable special handling and disposable procedures. 1 Instructions for Preparation The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see DOSAGE AND ADMINISTRATION). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

NOTE TO PHARMACIST: Exercise caution to prevent inadvertent cisplatin overdosage. Please call prescriber if dose is greater than 100 mg/m 2 per cycle. Aluminum flip-off seal of vial have been imprinted with the following statement: CALL DR. IF DOSE > 100 MG/M 2 /CYCLE. Administration Administer cisplatin injection by slow intravenous infusion.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

2.5 Dose Modifications Consider alternative treatments or dose reductions for patients with impaired creatinine clearance, myelosuppression, or neuropathy.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Ototoxic effects may be more severe and detrimental in pediatric patients receiving cisplatin injection, particularly in patients less than 5 years of age. Consider audiometric and vestibular function monitoring in all patients receiving cisplatin injection. The prevalence of hearing loss in pediatric patients is particularly high and is estimated to be 40% to 60%. Earlier detection of hearing loss can limit the potential impact of hearing impairment on a pediatric patient’s cognitive and social development [see Warnings and Precautions (5.6)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use For the treatment of metastatic testicular tumors or advanced bladder cancer, clinical studies of cisplatin injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In four clinical trials of combination chemotherapy for advanced ovarian carcinoma, 1,484 patients received cisplatin either in combination with cyclophosphamide or with paclitaxel.

Of these, 426 (29%) were older than 65 years. In these trials, age was not found to be a prognostic factor for survival. However, in a later secondary analysis for one of these trials, geriatric patients were found to have shorter survival compared with younger patients. In all four trials, geriatric patients experienced more severe neutropenia than did younger patients.

Higher incidences of severe thrombocytopenia and leukopenia were also seen in geriatric patients compared with younger patients, although not in all cisplatin-containing treatment arms. In the two trials where nonhematologic toxicity was evaluated according to age, geriatric patients had a numerically higher incidence of peripheral neuropathy than did younger patients.

Other reported clinical experience suggests that geriatric patients may be more susceptible to nephrotoxicity, myelosuppression, and infectious complications than are younger patients [see Warnings and Precautions (5.1, 5.2, 5.4)]. Cisplatin is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.

Administration

2.6 Preparation, Handling, and Administration Do not use needles or intravenous sets containing aluminum parts that can come in contact with cisplatin injection during preparation or administration. Aluminum reacts with cisplatin injection, causing precipitate formation and a loss of potency. Cisplatin injection is a cytotoxic drug. Follow applicable special handling and disposable procedures. 1 Instructions for Preparation The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see DOSAGE AND ADMINISTRATION ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. NOTE TO PHARMACIST: Exercise caution to prevent inadvertent cisplatin overdosage. Please call prescriber if dose is greater than 100 mg/m 2 per cycle. Aluminum flip-off seal of vial have been imprinted with the following statement: CALL DR. IF DOSE > 100 MG/M 2 /CYCLE. Administration Administer cisplatin injection by slow intravenous infusion.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 1 mg/mL (10 mg/10 mL and 50 mg/50 mL, 1 mg/mL (50 mg/50 mL
  • ) solution for iv infusion: 1 mg/mL (10 mg/10 mL, 1 mg/mL (10 mg/10 mL and 50 mg/50 mL, 1 mg/mL (50 mg/50 mL, 500 mcg/mL (10 mg/20 mL
  • Solution for injection: 1 mg/mL
  • Lyophilized powder for injection: 10 mg, 50 mg
  • ) concentrate for iv infusion: 0.5 mg/mL (10 mg/20 mL, 50 mg/100 mL (0.5 mg/mL
  • ) solution for injection for i.v. infusion: 1 mg/mL (50 mg/50 mL
  • Concentrate solution for iv infusion: 1 mg/mL
  • Solution for intravenous infusion: 1 mg/mL
  • Solution for iv infusion: 1 mg/mL
  • ) concentrate for solution for infusion: 1 mg/mL (50 mg/50 mL

and 5 more forms; see the products table.

Registered products in the Philippines

41 products registered with the Food and Drug Administration (FDA) Philippines list Cisplatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products41
Philippine FDA-registered products for Cisplatin
Package insert
Blatin 10Cisplatin
1 mg/mL Concentrate Solution for IV Infusion10 mL Type I moulded amber color glass vial sealed with grey bromo butyl rubber stopper and blue aluminum flip-off seal (Box of l's)
RxVAT-exempt
Venus RemediesIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-11641
Apr 5, 2027
Blatin 50Cisplatin
1 mg/mL Concentrate Solution for IV Infusion50 mL Type I moulded amber color glass vial sealed with grey bromo butyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Venus RemediesIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-11640
Apr 5, 2027
CelplatCisplatin
1 mg/mL (10 mg/ 10 mL and 50 mg/ 50 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass vial with red flip-off seal x 10 mL & 50 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Pvt. Ltd.India
I.E. Medica, Inc.
DRP-6633
Apr 11, 2031
Cesalin 50Cisplatin
50 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial x 50 mL with Gray Rubber Stopper and Yellow Flip-Off Seal (Box of 1's)
RxVAT-exempt
Techno Drugs LimitedBangladesh
Bridgemark Marketing
DR-XY42728
Oct 2, 2028
ChemojectCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ambicare Pharmaceuticals Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924-04
Nov 14, 2028
CidiamineCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ambitech Biopharmaceuticals Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924-03
Nov 14, 2028
Cilatin 50Cisplatin
1mg/mL (50mg/50mL) Solution for Injection (IV Infusion)60 ml-capacity USP Type 1 amber glass vial with 20 mm gray rubber stopper and 20 mm purple aluminum flip off seal x 50 mL (Box of 1's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-9113
Oct 2, 2030
Cis Spal-L 50Cisplatin
1 mg/mL (50 mg/50 mL) Concentrate Solution for IV InfusionType I amber glass vial with serum laminated. chlorobutyl rubber stopper and plastic purple C/L Alu seal (Box of 1 vial x 50 mL)
RxVAT-exempt
SP Accure Labs., Pvt. LtdIndia
Hexagon Pharmaceuticals
DRP-15084
Apr 17, 2029
CisaphtinCisplatin
50 mg Lyophilized Powder for IV Infusion50 mL-capacity type I clear glass vial with grey bromobutyl rubber stopper and blue flip-off seal (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-14421
Sep 6, 2028
Cisaphtin-10Cisplatin
10 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11189
Feb 11, 2027
Cisaphtin-50Cisplatin
1 mg/mL (10 mg/10 mL and 50 mg/50 mL) Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL and 50 mL (Box of l's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11188
Feb 11, 2027
CisbilCisplatin
1 mg/mL (10 mg/ 10 mL) Concentrate for Solution for Intravenous Infusion10 mL amber-colored Type I glass vial with gray serum stopper sealed with easy-to-open Alu with purple plastic cap (Box of l's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd
DR-XY47492
Nov 18, 2026
Cispa-50Cisplatin
1mg/mL Solution for IV InfusionUSP Type I Amber Vial with Grey Rubber Stopper and Aluminum Flip-Off Seal x 50 mL (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch Office
DRP-8250
Jul 1, 2029
Cispla-50Cisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
OneGen PharmaImporter: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924-01
Nov 14, 2028
CisplagetCisplatin
1mg/mL (10mg/10mL and 50mg/50mL) Solution For IV InfusionFlint type I amber glass vial x 10 mL and 50 mL with rubber stopper and aluminum pink flip-off seal (Box of 1’s)
RxVAT-exempt
Beta Drugs LimitedIndia
ZMG Incorporated
DRP-18401
Jul 29, 2032
CisplagetCisplatin
500 mcg/mL (10 mg/20 mL) Solution for IV InfusionUSP type I amber glass vial x 20 mL (Box of 1’s) plug and 20 mm D-Pink colour flip off seal.
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-18528
Jul 29, 2032
CisplaxilCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Globo Asiatico Enterprises, Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924-05
Nov 14, 2028
CisplaxonCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Diafarm Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924-02
Nov 14, 2028
CispollenCisplatin
10 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11189-01
Feb 11, 2027
CisteenCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL and 10 mL Type I Amber glass Vial with rubber stopper and violet flip-off seal in individual box
RxVAT-exempt
Naprod Lifesciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-2717
Mar 3, 2028
CistiplaxCisplatin
1 mg/mL Solution for Intravenous (IV) InfusionType I Amber Glass Vial with Grey Bromobutyl Rubber Stopper Sealed with Aluminum Seal and White Flip-off Cap x 10mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Diafarm Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation
DRP-5835-01
Nov 21, 2029
CizcanCisplatin
1 mg/mL Concentrate for Solution for Injection (IV)Amber-colored USP Type I Glass Vial with Green Flip-off Seal x 10 mL & 50 mL (Box of 1’s)
RxVAT-exempt
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-7089
Mar 10, 2032
CytosplatCisplatin
1 mg/mL (10 mg/10 mL and 50 mg/50 mL) Solution for IV InfusionAmber Glass Vial with Chlorobutyl Rubber Stopper and Aluminum Seal with Red Plastic Flip-off Cap x 10 mL and 50 mL (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DR-XY25047
Mar 31, 2028
EbeplatinCisplatin
0.5mg/mL (10mg/20mL) Concentrate For IV InfusionAmber glass vial with yellow flip-off seal x 20 mL (Box of 1’s)
RxVAT-exempt
Fareva Unterach GmbHAustria
Sandoz Philippine Corporation
DR-XY25485
Aug 12, 2027
EbeplatinCisplatin
50mg/100mL (0.5mg/mL) Concentrate For IV InfusionAmber glass vial x 100 mL with rubber stopper and yellow flip-off seal (Box of 1’s)
RxVAT-exempt
Fareva Unterach GmbHAustria
Sandoz Philippine Corporation
DR-XY25483
Aug 12, 2027
LixiplacilCisplatin
1 mg/mL (10 mg/10 mL) Solution for IV InfusionAmber USP Type I Glass Vial with grey bromobutyl rubber stopper, aluminum sealed and white flip-off cap x 10 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Globo Asiatico Enterprises, Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation
DRP-5835-02
Nov 21, 2029
MedplatinCisplatin
500 mcg/mL (10 mg/20 mL) Solution for IV Infusion20 mL USP Type I Amber Colored Glass Vial with Bromobutyl Rubber Stopper and Flip-off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Medinova Pharmaceutical Inc.
DRP-13183
Dec 16, 2027
NeoplatinCisplatin
1 mg / mL Solution for Injection10ml Amber Glass Vial (Box of 1’s)
RxVAT-exempt
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DRP-15581
Jan 6, 2029
NeoplatinCisplatin
1 mg/mL Solution for Injection10 mL Amber Glass Vial (Box of 1's)
RxVAT-exempt
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DR-XY42670
Jan 6, 2029
noneCisplatin
1mg/mL Concentrate Solution For I.V. InfusionType I amber glass vial x 10 mL with rubber stopper and aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Healol Pharma Corporation
DRP-14006
Jun 5, 2028
NoneCisplatin
500 mcg / mL (10 mg/20 mL) Solution for IV Infusion20 mL USP Type I Amber Colored Glass Vial with Bromobutyl Rubber Stopper and Flip-off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-13183-01
Dec 16, 2027
PlaticinCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection (I.V. Infusion)50 mL USP Type I Amber Glass Vial with Green Flip-off Seal) (Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
Genace Pharma DistributorImporter: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4924
Nov 14, 2028
PlaticinCisplatin
1 mg/mL Solution for Intravenous (IV) InfusionType I Amber Glass Vial with Grey Bromobutyl Rubber Stopper Sealed with Aluminum Seal and White Flip-off Cap x 10mL Box of 1's
RxVAT-exempt
Getwell PharmaceuticalsIndia
Genace Pharma DistributorImporter: AGB Pharmaceutical Trading and Consultancy Corporation
DRP-5835
Nov 21, 2029
PlatifirstCisplatin
1 mg/mL (50 mg/50 mL) Solution for Injection for I.V. InfusionUSP Type I Amber Moulded Glass Vial with Grey Butyl Rubber Stopper and Blue Flip-off Aluminum Seal x 50 mL (Box of 1's)
RxVAT-exempt
VHB Medi Sciences LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-12471
Aug 16, 2027
PlatihexCisplatin
1 mg/mL (50 mg/50 mL) Concentrate for Solution for Infusion (IV)Amber glass vial with grey chlorobutyl rubber stopper and purple flip-off seal x 50 mL (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd.
DRP-11745
Apr 25, 2027
PlatinCisplatin
1 mg/mL (50mg/50mL) Solution for Injection for I.V. InfusionUSP Type I Amber Moulded Glass Vial with Grey Butyl Rubber Stopper and Blue Flip-Off Aluminum Seal x 50 mL (Box of 1's)
RxVAT-exempt
VHB Medi Sciences LimitedIndia
Oncolife CorporationImporter: Endure Medical, Inc.
DRP-12471-01
Aug 16, 2027
PlatinCisplatin
1 mg/mL Solution for Injection (I.V. Infusion)Amber glass vial x 50mL (Box of 1's)
RxVAT-exempt
Intas Pharmaceutical LimitedIndia
Oncolife Corporation
DR-XY35396
Feb 4, 2032
PlatisanCisplatin
1 mg/mL Solution for Injection (IV)USP Type III Amber Glass Vial x 10 mL and 50 mL Box of 1's
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-10190
Sep 11, 2029
ZahirCisplatin
1 mg/mL Solution for injection (IV)USP Type III Amber Glass vial x 10 mL and 50 mL (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: Medethix, Inc.
DRP-10190-01
Sep 11, 2029
(no brand name)Cisplatin
1 mg/mL (50mg/50mL) Solution for IV InfusionUSP Type I Amber Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Hospira Australia Pty. LtdAustralia
Importer: Pfizer, Inc.
DR-XY2787
Oct 17, 2029
(no brand name)Cisplatin
1 mg/mL Solution for IV InfusionType I amber glass vial x 50 mL with rubber stopper and aluminum blue flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Healol Pharma Corporation
DRP-14874
Jan 29, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Cisplatin injection, USP, is a clear, colorless to pale yellow, sterile aqueous solution available in sterilie multiple-dose vials containing 50 mg/50 mL (1 mg/mL) 100 mg/100 mL (1 mg/mL) Cisplatin injection, USP, is multiple-dose vials containing 50 mg/50 mL (1 mg/mL) (3) 100 mg/100 mL (1 mg/mL) (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Hypersensitivity reactions: Anaphylaxis and death may occur; monitor for and treat accordingly (5.5)
  • Ototoxicity: Cumulative toxicity may be severe particularly in pediatric patients; consider audiometric and vestibular function monitoring (5.6, 8.4)
  • Ocular toxicity: Optic neuritis, papilledema, and cortical blindness may occur (5.7)
  • Secondary leukemia: Secondary acute leukemia may occur (5.8)
  • Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (5.9, 8.1, 8.3)
5.1 Nephrotoxicity

5.1 Nephrotoxicity Cisplatin injection can cause dose-related nephrotoxicity, including acute renal failure that becomes more prolonged and severe with repeated courses of the drug. Renal toxicity typically begins during the second week after a dose of cisplatin injection. Patients with baseline renal impairment, geriatric patients, patients who are taking other nephrotoxic drugs, or patients who are not well hydrated may be more susceptible to nephrotoxicity [see Use in Specific Populations (8.5, 8.6)].

Ensure adequate hydration before, during, and after cisplatin injection administration [see Dosage and Administration (2.1)]. Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes including magnesium prior to initiating therapy, and as clinically indicated. Consider magnesium supplementation as clinically needed.

Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines [see Dosage and Administration (2.5)].

5.2 Peripheral Neuropathy

5.2 Peripheral Neuropathy Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neurologic symptoms have been reported to occur after a single dose. Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.

Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. The neuropathy may progress further even after stopping treatment. Peripheral neuropathy may be irreversible in some patients. Perform a neurological examination before initiating cisplatin injection, at appropriate intervals during therapy, and after completion of therapy.

Consider discontinuation of cisplatin injection for patients who develop symptomatic peripheral neuropathy. Geriatric patients may be more susceptible to peripheral neuropathy [see Use in Specific Populations (8.5)].

5.3 Nausea and Vomiting

5.3 Nausea and Vomiting Cisplatin injection is a highly emetogenic antineoplastic agent. Premedicate with anti-emetic agents [see Dosage and Administration (2.1)]. Without antiemetic therapy, marked nausea and vomiting occur in almost all patients treated with cisplatin injection and may be so severe that the drug must be discontinued.

Nausea and vomiting may begin within 1 to 4 hours after treatment and last up to 72 hours. Maximal intensity occurs 48 to 72 hours after administration. Various degrees of vomiting, nausea, and/or anorexia may persist for up to 1 week after treatment. Delayed nausea and vomiting (begins or persists 24 hours or more after chemotherapy) has occurred in patients attaining complete emetic control on the day of cisplatin injection therapy.

Consider the use of additional anti-emetics following infusion.

5.4 Myelosuppression

5.4 Myelosuppression Myelosuppression suppression occurs in 25% to 30% of patients treated with cisplatin injection. Fever and infection have been reported in patients with neutropenia. Potential fatalities due to infection (secondary to myelosuppression) have been reported. Geriatric patients may be more susceptible to myelosuppression [see Use in Specific Populations (8.5)].

Perform standard hematologic tests before initiating cisplatin injection, before each subsequent course, and as clinically indicated. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with cisplatin injection. For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.

5.5 Hypersensitivity Reactions

5.5 Hypersensitivity Reactions Cisplatin injection can cause severe hypersensitivity reactions, including anaphylaxis and death. Manifestations have included facial edema, wheezing, tachycardia, and hypotension. Hypersensitivity reactions have occurred within minutes of administration to patients with prior exposure tocisplatin injection.

Monitor patients receiving cisplatin injection for possible hypersensitivity reactions. Ensure supportive equipment and medications are available to treat severe hypersensitivity reactions. Severe hypersensitivity reactions require immediate discontinuation of cisplatin injection and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with cisplatin injection [see Contraindications (4)].

Cross-reactivity between platinum-based antineoplastic agents has been reported. Cases of severe hypersensitivity reactions have recurred after rechallenging patients with a different platinum agent.

5.6 Ototoxicity

5.6 Ototoxicity Cisplatin injection can cause ototoxicity, which is cumulative and may be severe. Consider audiometric and vestibular function monitoring. Ototoxicity is manifested by tinnitus, hearing loss in the high frequency range (4,000 to 8,000 Hz) and/or decreased ability to hear normal conversational tones. Ototoxicity can occur during or after treatment and can be unilateral or bilateral.

Deafness after the initial dose of cisplatin injection has been reported. Vestibular toxicity has also been reported. Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age. The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.

Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment. Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin [see Use in Specific Populations (8.4)]. Genetic factors (e.g. variants in the thiopurine S-methyltransferase [TPMT] gene) may also contribute to the cisplatin-induced ototoxicity; although this association has not been consistent across populations and study designs.

5.7 Ocular Toxicity

5.7 Ocular Toxicity Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection. Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection. The altered color perception manifests as a loss of color discrimination, particularly in the blue-yellow axis and irregular retinal pigmentation of the macular area on fundoscopic exam.

Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.

5.8 Secondary Malignancies

5.8 Secondary Malignancies The development of acute leukemia secondary to the use of cisplatin injection has been reported. In these reports, cisplatin injection was generally given in combination with other leukemogenic agents.

5.9 Embryo-Fetal Toxicity

5.9 Embryo-Fetal Toxicity Based on human data, cisplatin injection can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 14 months after the last dose of cisplatin injection.

Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months after the last dose of cisplatin injection [see Use in Specific Populations (8.1, 8.3)].

5.10 Injection Site Reactions

5.10 Injection Site Reactions Injection site reactions can occur during the administration of cisplatin injection. Local soft tissue toxicity has been reported following extravasation of cisplatin injection. Severity of the local tissue toxicity appears to be related to the concentration of the cisplatin injection solution.

Infusion of solutions with a cisplatin injection concentration greater than 0.5 mg/mL may result in tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. Because of the possibility of extravasation, closely monitor the infusion site during drug administration.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS The following drug interactions are described in other sections: Nephrotoxic drugs [see Warnings and Precautions (5.1)] Ototoxic drugs [see Warnings and Precautions (5.6)]

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following adverse reactions are described in greater detail, in other sections: Nephrotoxicity [see Warnings and Precautions (5.1)] Peripheral Neuropathy [see Warnings and Precautions (5.2)] Nausea and vomiting [see Warnings and Precautions (5.3)] Myelosuppression [see Warnings and Precautions (5.4)] Hypersensitivity reactions [see Warnings and Precautions (5.5)] Ototoxicity [see Warnings and Precautions (5.6] Ocular toxicity [see Warnings and Precautions (5.7)] Secondary malignancies [see Warnings and Precautions (5.8)] Injection site reactions [see Warnings and Precautions (5.10)] Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting myelosuppression, and ototoxicity. The following adverse reactions have been identified from clinical trials or post-marketing surveillance.

Blood and lymphatic system disorders: Coombs‑positive hemolytic anemia. hemolytic uremic syndrome, thrombotic thrombocytopenic purpura Cardiovascular disorders: Venous thromboembolism, arterial thromboembolism, myocardial infarction, cerebrovascular accident, thrombotic microangiopathy, cerebral arteritis, pericardial effusion, cardiac failure, ventricular dysfunction, Raynaud’s phenomenon Eye disorders: Optic neuritis, papilledema, cortical blindness, blurred vision, color blindness, retinal pigmentation Gastrointestinal disorders: Nausea, vomiting, anorexia, diarrhea, stomatitis, gastrointestinal perforation, pancreatitis, hiccups General disorders: Asthenia, malaise Hepatobiliary disorders: Elevations of aminotransferases, lactate dehydrogenase, and bilirubin; hepatic failure Hypersensitivity: Anaphylaxis, facial edema, wheezing, tachycardia, and hypotension Local Site Reactions: Tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema Metabolism and nutrition disorders: Hypomagnesemia, often requiring magnesium supplementation; hyperuricemia, other electrolyte abnormalities (hypocalcemia, hyponatremia, hypokalemia, and hypophosphatemia), Syndrome of Inappropriate Antidiuretic Hormone Excretion (SIADH), dehydration, tumor lysis syndrome, increased serum amylase Musculoskeletal disorders: Muscle cramps (localized, painful, involuntary skeletal muscle contractions of sudden onset and short duration) Nervous system disorders: Peripheral neuropathy, Encephalopathy, loss of motor function, loss of taste, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome, progressive multifocal leukoencephalopathy, seizures, Lhermitte’s sign, dorsal column myelopathy, autonomic neuropathy, seizures, involuntary skeletal muscle contractions, tetany (with hypocalcemia and hypomagnesemia) Ototoxicity: Tinnitus, hearing loss, deafness, vestibular toxicity Renal and urinary disorders: Nephrotoxicity including renal failure, renal electrolyte wasting, azotemia, decreased creatinine clearance Respiratory disorders: pneumonitis/interstitial lung disease, pulmonary embolism Skin and subcutaneous tissue disorders: Alopecia, rash Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting, myelosuppression, and ototoxicity. (6) To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on human data from published literature, cisplatin injection can cause fetal harm when administered to pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Data demonstrates transplacental transfer of cisplatin. Exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth.

Cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. Cisplatin injection administration to animals during and after organogenesis resulted in teratogenicity. A published study in mice showed placental transfer of cisplatin increased with placenta maturation. The background risk of major birth defects and miscarriage for the indicated populations are unknown.

However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.

Mechanism of action

12.1 Mechanism of Action The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more.

Maximum red blood cell concentrations of platinum are reached within 90 to 150 minutes after a 100 mg/m 2 dose of cisplatin and decline in a biphasic manner with a terminal half-life of 36 to 47 days.

Elimination Over a dose range of 40 mg to 140 mg cisplatin per m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours.

Over 5 days following administration of 40 mg/m 2 to 100 mg/m 2 doses given as rapid, 2 to 3 hour or 6 to 8 hour infusions, a mean of 35% to 51% of the dosed platinum is excreted in the urine.

Similar mean urinary recoveries of platinum of about 14% to 30% of the dose are found following 5 daily administrations of 20 mg/m 2 per day, 30 mg/m 2 per day, or 40 mg/m 2 per day.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution Cisplatin dose not undergo the instantaneously and reversible binding to plasma protein that is characteristic of normal drug-protein binding. Platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin.

Three hours after a bolus injection and 2 hours after the end of a 3 hour infusion, 90% of the plasma platinum is protein bound. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more. Following cisplatin doses of 20 mg/m 2 to 120 mg/m 2, platinum is present in tissues for as long as 180 days after the last administration.

With the exception of intracerebral tumors, platinum concentrations in tumors are generally somewhat lower than the concentrations in the organ where the tumor is located. Hepatic metastases have the highest platinum concentrations, but these are similar to the platinum concentrations in normal liver. Maximum red blood cell concentrations of platinum are reached within 90 to 150 minutes after a 100 mg/m 2 dose of cisplatin and decline in a biphasic manner with a terminal half-life of 36 to 47 days.

Metabolism The chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism. At physiological pH, the predominant molecular species are cisplatin and monohydroxymonochloro cis -diamine platinum (II) in nearly equal concentrations.

The latter, combined with the possible direct displacement of the chlorine atoms by sulfhydryl groups of amino acids or proteins, accounts for the instability of cisplatin in biological matrices. The ratios of cisplatin to total free (ultrafilterable) platinum in the plasma vary considerably between patients and range from 0.5 to 1.1 after a dose of 100 mg/m 2.

Elimination Over a dose range of 40 mg to 140 mg cisplatin per m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours. Over 5 days following administration of 40 mg/m 2 to 100 mg/m 2 doses given as rapid, 2 to 3 hour or 6 to 8 hour infusions, a mean of 35% to 51% of the dosed platinum is excreted in the urine.

Similar mean urinary recoveries of platinum of about 14% to 30% of the dose are found following 5 daily administrations of 20 mg/m 2 per day, 30 mg/m 2 per day, or 40 mg/m 2 per day. Only a small percentage of the administered platinum is excreted beyond 24 hours post-infusion and most of the platinum excreted in the urine in 24 hours is excreted within the first few hours.

The parent compound, cisplatin, is excreted in the urine and accounts for 13% to 17% of the dose excreted within 1 hour after administration of 50 mg/m 2. The mean renal clearance of cisplatin exceeds creatinine clearance and was 62 mL/min per m 2 and 50 mL/min per m 2 following administration of 100 mg/m 2 as 2 hour or 6 to 7 hour infusions, respectively.

Plasma concentrations of the parent compound, cisplatin, decrease monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 mg/m 2 or 100 mg/m 2 doses. Monoexponential decreases and plasma half-lives of about 0.5 hour are also seen following 2 hour or 7 hour infusions of 100 mg/m 2.

After the latter, the total body clearances and volumes of distribution at steady-state for cisplatin are about 15 Liters per hour per m 2 to 16 Liters per hour per m 2 and 11 Liters per m 2 to 12 Liters per m 2. The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate, indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys.

The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption. No significant relationships exist between the renal clearance of either free platinum or cisplatin and creatinine clearance.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Cisplatin 1 mg/mL, 10 mL Vial₱160.00–₱179.00Reference ₱160.00per vialDPRI procurement range
Cisplatin 1 mg/mL, 50 mL Vial₱312.22–₱650.00Reference ₱366.17per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Cisplatin
PNF listingInj.: 1 mg/mL, 10 mL and 50 mL vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Cisplatin · Accord Healthcare Inc. [US FDA-approved label, version 6, December 3, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b029f5-0d7e-4e7f-accc-b722aec34c68
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .